2CB-Ind

2CB-Ind
Systematic (IUPAC) name
(5-bromo-4,7-dimethoxy-2,3-dihydro-1H-inden-1-yl)methanamine
Clinical data
Routes of
administration		 Oral
Legal status
  • Uncontrolled
Identifiers
CAS Number 912342-23-5 N
ATC code none
PubChem CID 16086368
ChemSpider 17245022 YesY
ChEMBL CHEMBL424890 YesY
Chemical data
Formula C12H16BrNO2
Molar mass 286.164 g/mol
 NYesY (what is this?)  (verify)

2CB-Ind is a conformationally-restricted derivative of the phenethylamine hallucinogen 2C-B, discovered in 1974 by Alexander Shulgin. It acts as a moderately potent and selective agonist for the 5-HT2A and 5-HT2C receptors, but unlike the corresponding benzocyclobutene derivative TCB-2 which is considerably more potent than the parent compound 2C-B, 2CB-Ind is several times weaker, with racemic 2CB-Ind having a Ki of 47nM at the human 5-HT2A receptor, only slightly more potent than the mescaline analogue (R)-jimscaline.[1][2]

See also

References

  1. ↑ McLean, TH; et al. (2006). "1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists". Journal of Medicinal Chemistry 49 (19): 5794–803. doi:10.1021/jm060656o. PMID 16970404.
  2. ↑ Braden, Michael Robert (2007). Towards a biophysical understanding of hallucinogen action (PhD.). Purdue University.


This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.